GILD · Gilead Sciences, Inc.

Gilead’s Q1 2026 results reflect strong underlying commercial execution—particularly in HIV, where Biktarvy and Descovy delivered double-digit growth—and emerging momentum in oncology with Trodelvy’s 37% YoY increase. However, the earnings narrative is dominated by strategic transformation: the company completed the $7.8 billion Arcellx acquisition and announced definitive agreements for Tubulis and Ouro, collectively adding next-generation platforms in oncology (ADCs, BCMA-targeted therapies) and inflammation (TCEs). These transactions triggered a material revision to full-year guidance: GAAP EPS guidance shifted from positive $6.75–$7.15 to a projected loss of ($3.25)–($2.85), driven entirely by $11.5 billion in anticipated acquired IPR&D charges—a non-cash accounting expense that reflects the fair-value allocation of R&D assets acquired. While this distorts near-term GAAP profitability, management explicitly frames it as an investment in long-term growth, citing up to four potential 2026 product launches and five Phase 3 updates. The 8% YoY growth in base business (excluding Veklury) and 10% HIV growth underscore continued franchise strength, even as Veklury sales collapsed 52% due to declining pandemic-related demand. Product gross margin expanded 250 bps to 79.2%, aided by royalty obligation expiration and favorable mix. With $8.6 billion in cash as of March 31, Gilead retains significant financial flexibility to fund integration, R&D, and its $0.82 quarterly dividend—though operating cash flow ($2.5 billion) was more than offset by $2.8 billion in debt repayments, $1.0 billion in dividends, and $419 million in buybacks during the quarter.